Importantly, interfering with FABP4 or downstream metabolic consequences of FA translocation (e.g. inhibitors of FA oxidation) were shown to attenuate both AML survival66 and AML progression in vitro and in vivo.68 The gene discussed is FABP4; the disease is acute myeloid leukemia.